Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
You may also like
Manufacturing
LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener
Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Dosage Forms
AI-engineered nasal spray could block flu and COVID-19
Researchers have successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments, revealing a possible universal prevention platform for multiple respiratory viruses
Research & Development
CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration
Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Cell & Gene Therapy
Leucid Bio and Syenex team up for in vivo CAR-T cell engineering
The pair will harness Syenex’s VivoCell Platform to precisely deliver Leucid’s CAR-T asset LEU011 construct to T-cells in vivo, representing a next-generation approach and moving toward a simpler, possibly off-the-shelf administration route
Regulatory
Grifols gets nod from European Medicines Agency for entire value chain of Grifols Egypt
The institution's certification endorses the entire plasma value chain under the highest European standards and opens the door for Egypt to, once domestic needs are met, export to other markets including Europe
Regulatory
Regulating innovation: a new focus on digital mental health technologies (DMHTs)
IMed Consultancy’s Benjamin Austin provides a clear understanding of how digital mental health technologies are innovating care and describes the evolving regulatory frameworks that ensure their safety and effectiveness